Exploring Technology Transfer with Over 10 Multinational Pharmaceutical Companies
[Asia Economy Reporter Hyungsoo Park] The world's largest bio industry conference, '2022 BIO USA,' will be held from the 13th to the 16th in San Diego, USA. As this is the first fully in-person event in three years, interest in new drug technology transfer achievements has reached its peak.
According to STCube on the 9th, they will hold partnering meetings for the technology transfer of the immune checkpoint inhibitor ‘hSTC810’ with Pfizer, BMS, and others at BIO USA. They received pre-meeting requests from numerous multinational pharmaceutical companies and have confirmed individual meetings with about 10 companies.
BIO USA is the world's largest international bio event. Thousands of companies worldwide participate to share research results and discuss technological cooperation. For domestic new drug developers, it is an opportunity to showcase their technological capabilities globally and discuss technology exports with multiple multinational pharmaceutical companies.
This year, 20 domestic companies, including STCube, will participate. Along with Samsung Biologics, Celltrion, and Lotte Biologics, which recently entered the bio business, companies such as ABL Bio, VigenCell, Bridge Biotherapeutics, and JW Pharmaceutical will also participate.
An STCube official explained, “We received meeting requests from numerous big pharma companies,” adding, “We will hold partnering meetings for technology transfer with about 10 big pharma companies including Pfizer and BMS.” He continued, “With the clinical initiation of ‘hSTC810’ this year attracting great attention and this being the first offline event in three years, we expect active discussions with global big pharma companies.”
The immune checkpoint inhibitor ‘hSTC810’ is STCube’s core pipeline. Since it is expressed mutually exclusively with the existing immune checkpoint inhibitor PD-L1, it is evaluated as a groundbreaking treatment for cancer patients who are unresponsive to existing therapies. Following the first patient dosing in April, clinical phase 1 trials have officially commenced in the US and domestically.
Based on the excellent preclinical results of ‘hSTC810,’ STCube has set a goal to simultaneously succeed in phase 1 clinical trials and technology transfer this year. To promote successful clinical progress, they have also secured operating funds amounting to 47.6 billion KRW.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
